This course has expired. View available courses.
Endocrinology
Beyond glycaemic management – the role of SGLT2i in the T2D treatment algorithm – ACRRM
With the newly-released 2020 ADS/RACGP Australian diabetes treatment guideline presents new treatment opportunities for Australian clinicians and their patients with diabetes. In this program, you will get to know the most current diabetes management guidelines, and cover the clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function. With a focus on how […]
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
ACRRM
EXPIRY DATE
2022-08-09
With the newly-released 2020 ADS/RACGP Australian diabetes treatment guideline presents new treatment opportunities for Australian clinicians and their patients with diabetes. In this program, you will get to know the most current diabetes management guidelines, and cover the clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function.
With a focus on how to individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, this program covers how to differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations.
This program is supported by independent educational grants provided by Boehringer Ingelheim and Eli Lilly.
Faculty
Dr Anita Sharma (GP)
MBBS, FRACGP
Dr Esther Briganti (Endocrinologist)
MBBS, MClinEpi, PhD, FRACP
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the 2020 Royal Australian College of General Practitioners (RACGP) diabetes management guidelines, including clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function
- Differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations
- Individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, including cardiovascular disease, heart failure, impaired renal function, hypertension and obesity
- Identify situations in which specific glucose-lowering medicines may be contraindicated or require cessation
Accreditation
This PDP Activity is accredited by The Australian College of Rural & Remote Medicine for 1 hour of Educational Activity.
ACRRM ID: 24947